Joel Greenblatt Amicus Therapeutics, Inc. Transaction History

Gotham Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$11.78 - $13.86 $66,580 - $78,336	-5,652 Reduced 34.76%	10,606 $128,000
Q2 2023 Aug 14, 2023	SELL	$10.72 - $13.3 $216,994 - $269,218	-20,242 Reduced 55.46%	16,258 $204,000
Q1 2023 May 15, 2023	BUY	$10.91 - $13.54 $201,464 - $250,029	18,466 Added 102.4%	36,500 $404,000
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $178,356 - $229,031	18,034 New	18,034 $220,000
Q2 2022 Aug 15, 2022	BUY	$6.23 - $11.12 $72,025 - $128,558	11,561 New	11,561 $124,000
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $207,948 - $328,922	-26,356 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.82 - $12.44 $93,653 - $118,640	9,537 Added 56.7%	26,356 $304,000
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $146,998 - $199,136	16,819 New	16,819 $161,000
Q2 2019 Aug 14, 2019	SELL	$10.96 - $14.4 $121,075 - $159,076	-11,047 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$10.04 - $13.92 $110,911 - $153,774	11,047 New	11,047 $150,000

312

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.64B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.